Table 2.
Short- and long-term offspring outcomes in the HDP and non-HDP groups - univariate analysis.
| HDP | Non-HDP | |||||
|---|---|---|---|---|---|---|
| ACS | No-ACS | Crude OR (95% CI) | ACS | No-ACS | Crude OR (95% CI) | |
| Short-term outcomes | (N = 2,609) | (N = 2,197) | (N = 9,653) | (N = 6,555) | ||
| In-hospital death (%) | 68/2,608 (2.6) | 81/2,196 (3.7) | 0.70 (0.50–0.97) | 322/9,646 (3.3) | 360/6,555 (5.5) | 0.59 (0.51–0.69) |
| Respiratory distress syndrome (%) | 1,749/2,608 (67.1) | 1,543/2,196 (70.3) | 0.86 (0.76–0.97) | 5,757/9,633 (59.8) | 4,426/6,548 (67.6) | 0.71 (0.67–0.76) |
| Chronic lung disease (%) | 673/2,586 (26.0) | 428/2,178 (19.7) | 1.44 (1.25–1.65) | 2,682/9,566 (28.0) | 1,338/6,493 (20.6) | 1.50 (1.39–1.62) |
| Intraventricular haemorrhage (III or IV) (%) | 51/2,597 (2.0) | 55/2,189 (2.5) | 0.78 (0.53–1.14) | 334/9,603 (3.5) | 418/6,511 (6.4) | 0.53 (0.45–0.61) |
| Periventricular leukomalacia (%) | 67/2,602 (2.6) | 48/2,190 (2.2) | 1.18 (0.81–1.72) | 293/9,620 (3.0) | 336/6,529 (5.1) | 0.58 (0.49–0.68) |
| Sepsis (%) | 160/2,603 (6.1) | 152/2,188 (6.9) | 0.88 (0.70–1.10) | 782/9,631 (8.1) | 607/6,538 (9.3) | 0.86 (0.77–0.96) |
| Necrotizing enterocolitis (%) | 28/2,608 (1.1) | 34/2,194 (1.5) | 0.69 (0.42–1.14) | 149/9,632 (1.5) | 101/6,545 (1.5) | 1.00 (0.78–1.29) |
| Composite adverse outcomes (%) | 162/2,609 (6.2) | 159/2,197 (7.2) | 0.85 (0.68–1.06) | 826/9,653 (8.6) | 931/6,555 (14.2) | 0.57 (0.51–0.62) |
| Long-term outcomes | (N = 1,031) | (N = 882) | (N = 3,746) | (N = 2,576) | ||
| Death after NICU discharge (%) | 8/1,031 (0.8) | 4/882 (0.5) | 1.72 (0.52–5.72) | 37/3,746 (1.0) | 28/2,576 (1.1) | 0.91 (0.55–1.49) |
| Home oxygen therapy/home respiratory therapy (%) | 14/892 (1.6) | 14/731 (1.9) | 0.82 (0.39–1.70) | 68/3,111 (2.2) | 36/2,024 (1.8) | 1.23 (0.82–1.86) |
| Visually impairment (%) | 47/942 (5.0) | 36/827 (4.4) | 1.15 (0.74–1.80) | 1,91/3,402 (5.6) | 142/2,347 (6.1) | 0.92 (0.74–1.16) |
| Hearing impairment (%) | 4/713 (0.6) | 6/631 (1.0) | 0.61 (0.18–2.04) | 42/2,725 (1.5) | 38/1,793 (2.1) | 0.72 (0.46–1.13) |
| Cerebral palsy (%) | 58/975 (5.9) | 46/851 (5.4) | 1.11 (0.74–1.65) | 271/3,510 (7.7) | 259/2,458 (10.5) | 0.71 (0.59–0.85) |
| Developmental quotient <70 (%) | 117/743 (15.7) | 93/593 (15.7) | 1.00 (0.75–1.35) | 416/2,612 (15.9) | 274/1,643 (16.7) | 0.95 (0.80–1.12) |
| Developmental quotient <85 (%) | 364/743 (49.0) | 268/593 (45.2) | 1.16 (0.94–1.45) | 1,283/2,612 (49.1) | 874/1,643 (53.2) | 0.85 (0.75–0.96) |
| Composite adverse outcomes (%) | 158/1,031 (15.3) | 131/882 (14.9) | 1.02 (0.80–1.29) | 648/3,746 (17.3) | 494/2,576 (19.2) | 0.88 (0.78–0.99) |
HDP, hypertensive disorders of pregnancy; ACS, antenatal corticosteroids; OR, odds ratio; Short-term composite adverse outcomes: in-hospital death, intraventricular haemorrhage (grade III or IV) and periventricular leukomalacia, Long-term composite adverse outcomes: death after NICU discharge, cerebral palsy and developmental quotient <70. Bold indicates a significant association.